Wash. Tribal Corp. Says Stanford Used Its IP For Drug Patent

By Sarah Jarvis (October 5, 2021, 6:48 PM EDT) -- The Tulalip Tribal Federal Corp. has alleged that Stanford University secretly duplicated a potential opioid addiction treatment that was based on research involving the tribes' confidential information and funding, and that the university applied for a provisional patent for a synthetic version of the drug.

TTFC, which is owned by the Tulalip Tribes, said in a Friday suit against the university's board of trustees that it inked an agreement in May 2018 to provide funding, confidential research information and proprietary data with Stanford's Behavioral and Functional Neuroscience Laboratory in hopes of developing an opioid addiction cure and patenting it under TTFC's...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!